{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T04:45:26Z","timestamp":1779165926517,"version":"3.51.4"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T00:00:00Z","timestamp":1750118400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.vhri.2025.101158","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T18:39:07Z","timestamp":1754591947000},"page":"101158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Cost-Effectiveness Analysis Comparing Ceftazidime\/Avibactam With Standard of Care in the Treatment of Hospital and Ventilator-Acquired Pneumonia in the Philippines"],"prefix":"10.1016","volume":"50","author":[{"given":"Rontgene M.","family":"Solante","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dionisio","family":"Tiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kezia","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia Hao","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaywei","family":"Low","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Evan","family":"Payawal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Winniefer","family":"Nua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.vhri.2025.101158_bib1","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3390\/jcm9010275","article-title":"Epidemiology, treatment, and prevention of nosocomial bacterial pneumonia","volume":"9","author":"Jean","year":"2020","journal-title":"J Clin Med"},{"key":"10.1016\/j.vhri.2025.101158_bib2","series-title":"Harrison\u2019s Principles of Internal Medicine","article-title":"Pneumonia","author":"Mandell","year":"2018"},{"key":"10.1016\/j.vhri.2025.101158_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ijid.2016.05.021","article-title":"Assessing the burden of pneumonia using administrative data from Malaysia, Indonesia, and the Philippines","volume":"49","author":"Azmi","year":"2016","journal-title":"Int J Infect Dis"},{"issue":"5","key":"10.1016\/j.vhri.2025.101158_bib4","doi-asserted-by":"crossref","first-page":"e61","DOI":"10.1093\/cid\/ciw353","article-title":"Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society","volume":"63","author":"Kalil","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.vhri.2025.101158_bib7","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.vhri.2025.101158_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1017\/S0266462314000117","article-title":"Markov modelling and discrete event simulation in health care: a systematic comparison","volume":"30","author":"Standfield","year":"2014","journal-title":"Int J Technol Assess Health Care"},{"key":"10.1016\/j.vhri.2025.101158_bib9","series-title":"Clinical equipment and devices","year":"2020"},{"issue":"6","key":"10.1016\/j.vhri.2025.101158_bib10","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1007\/s40265-018-0902-x","article-title":"Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections","volume":"78","author":"Shirley","year":"2018","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.vhri.2025.101158_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.106270","article-title":"Multicenter study of ceftolozane\/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients","volume":"57","author":"Balandin","year":"2021","journal-title":"Int J Antimicrob Agents"},{"issue":"05","key":"10.1016\/j.vhri.2025.101158_bib14","doi-asserted-by":"crossref","first-page":"476","DOI":"10.3855\/jidc.6195","article-title":"Colistin alone or combined with sulbactam or carbapenem against A. baumannii in ventilator-associated pneumonia","volume":"9","author":"Yilmaz","year":"2015","journal-title":"J Infect Dev Ctries"},{"issue":"12","key":"10.1016\/j.vhri.2025.101158_bib15","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"12","key":"10.1016\/j.vhri.2025.101158_bib16","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00592-18","article-title":"In vitro activity of ceftazidime-avibactam and aztreonam-avibactam against OXA-48-Carrying enterobacteriaceae isolated as part of the International Network for Optimal Resistance Monitoring (INFORM) global surveillance program from 2012 to 2015","volume":"62","author":"Kazmierczak","year":"2018","journal-title":"Antimicrob Agents"},{"issue":"3","key":"10.1016\/j.vhri.2025.101158_bib17","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1093\/jac\/43.3.389","article-title":"Piperacillin\/tazobactam nosocomial pneumonia study group. Piperacillin\/tazobactam plus tobramycin versus ceftazidime plus tobramycin for the treatment of patients with nosocomial lower respiratory tract infection","volume":"43","author":"Joshi","year":"1999","journal-title":"J Antimicrob Chemother"},{"issue":"10","key":"10.1016\/j.vhri.2025.101158_bib18","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s10096-006-0193-0","article-title":"Ertapenem versus cefepime for initial empirical treatment of pneumonia acquired in skilled-care facilities or in hospitals outside the intensive care unit","volume":"25","author":"Yakovlev","year":"2006","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"1","key":"10.1016\/j.vhri.2025.101158_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13054-015-0795-y","article-title":"Incidence and outcome of inappropriate in-hospital empiric antibiotics for severe infection: a systematic review and meta-analysis","volume":"19","author":"Marquet","year":"2015","journal-title":"Crit Care"},{"issue":"1","key":"10.1016\/j.vhri.2025.101158_bib20","article-title":"Influence of carbapenem resistance on mortality of patients with Pseudomonas aeruginosa infection: a meta-analysis","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.vhri.2025.101158_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247832","article-title":"Ventilator-associated pneumonia among ICU patients in WHO Southeast Asian region: a systematic review","volume":"16","author":"Kharel","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.vhri.2025.101158_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.jval.2019.09.879","article-title":"Cost-effectiveness of second-line ceftazidime-avibactam in patients with hospital-acquired pneumonia including ventilator-associated pneumonia in Taiwan","volume":"22","author":"Chen","year":"2019","journal-title":"Value Health"},{"issue":"5","key":"10.1016\/j.vhri.2025.101158_bib26","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.clinthera.2020.03.014","article-title":"Cost-effectiveness comparison of ceftazidime\/avibactam versus meropenem in the empirical treatment of hospital-acquired pneumonia, including ventilator-associated pneumonia, in Italy","volume":"42","author":"Tichy","year":"2020","journal-title":"Clin Ther"},{"issue":"1","key":"10.1016\/j.vhri.2025.101158_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200131","article-title":"Colistin monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms","volume":"2","author":"Kaye","year":"2023","journal-title":"NEJM Evid"},{"issue":"24","key":"10.1016\/j.vhri.2025.101158_bib28","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1016\/j.vaccine.2012.03.031","article-title":"The potential economic value of a Staphylococcus aureus vaccine among hemodialysis patients","volume":"30","author":"Song","year":"2012","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vhri.2025.101158_bib29","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1086\/318492","article-title":"The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus","volume":"32","author":"Delate","year":"2001","journal-title":"Clin Infect Dis"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000834?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212109925000834?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:48:08Z","timestamp":1762332488000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212109925000834"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":22,"alternative-id":["S2212109925000834"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101158","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-Effectiveness Analysis Comparing Ceftazidime\/Avibactam With Standard of Care in the Treatment of Hospital and Ventilator-Acquired Pneumonia in the Philippines","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2025.101158","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of International Society for Pharmacoeconomics and Outcomes Research, Inc.","name":"copyright","label":"Copyright"}],"article-number":"101158"}}